As substantial evidence has linked dysregulation of histone deacetylases with tumorigenesis [4,5], HDAC inhibitors have emerged as potential therapeutic agents for multiple types of human cancer due to their diverse modes of antitumor mechanisms [6]. This evidence concerns the gene HDAC9 and cancer.